Teva Pharmaceutical Industries (NYSE:TEVA) EVP Eliyahu Sharon Kalif Sells 153,251 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares in the company, valued at $6,131,472.24. This represents a 47.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Eliyahu Sharon Kalif also recently made the following trade(s):

• On Thursday, February 26th, Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $33.64, for a total value of $11,633,048.40.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $34.12 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a market capitalization of $39.23 billion, a PE ratio of 25.65, a P/E/G ratio of 3.29 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35. The business’s fifty day moving average price is $31.65 and its 200 day moving average price is $30.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $3.98 billion for the quarter. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Fitch upgraded Teva to investment grade, which may improve financing terms and highlights confidence in its turnaround execution. Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
• Positive Sentiment: Analyst commentary says Teva’s branded drug growth, biosimilars, and improving margins support a stronger long-term outlook. Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
• Neutral Sentiment: Teva released new data showing many younger adults with mood disorders and tardive dyskinesia remain undiagnosed, supporting awareness of the company’s neuroscience market opportunity. Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
• Negative Sentiment: An executive sold a sizable block of shares, which can weigh on sentiment even if it reflects routine portfolio activity. Eliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Analysts Set New Price Targets

Several brokerages have weighed in on TEVA. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. The Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Finally, Bank of America upped their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TEVA. Global Retirement Partners LLC grew its position in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after buying an additional 292 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock valued at $459,000 after buying an additional 302 shares during the last quarter. Banque Cantonale Vaudoise grew its position in shares of Teva Pharmaceutical Industries by 6.3% in the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after buying an additional 306 shares during the last quarter. Ethic Inc. grew its position in shares of Teva Pharmaceutical Industries by 1.8% in the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock valued at $566,000 after buying an additional 325 shares during the last quarter. Finally, Allworth Financial LP grew its position in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.